Oncologic Effect of Oral Fluorouracil in Hormone Receptor-Negative T1a Node-Negative Breast Cancer Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: As 5-fluorouracil (5-FU) has previously exhibited antitumor activity and few adverse effects in the treatment of breast cancer, we aimed to specifically assess the benefits of orally administered 5-FU in hormone receptor-negative small breast cancer. Methods: We retrospectively identified patients with pT1aN0 and hormone receptor-negative breast cancer who underwent surgery between 1993 and 2008 at Asan Medical Center. Patients were divided into two cohorts based on adjuvant doxifluridine (Didox; Shin Poong Pharm. Co., Ltd.) administration, and the disease-free survival (DFS) and cancer-specific survival (CSS) was assessed for each cohort. Results: Both cohorts had similar ages and tumor sizes. The DFS and CSS did not significantly differ between the groups (p=0.399 and p=0.126, respectively). When the cohorts were assessed according to human epidermal growth factor receptor 2 (HER2) status, doxifluridine significantly improved DFS among patients with T1aN0 and HER2-positive breast cancer (p=0.037). Conclusion: Doxifluridine did not yield a significant reduction in DFS events in hormone receptor-negative early breast cancer. However, a clear benefit was observed in hormone receptor-negative, HER2-positive T1aN0 breast cancer patients.
Abstract
Purpose: As 5-fluorouracil (5-FU) has previously exhibited antitumor activity and few adverse effects in the treatment of breast cancer, we aimed to specifically assess the benefits of orally administered 5-FU in hormone receptor-negative small breast cancer. Methods: We retrospectively identified patients with pT1aN0 and hormone receptor-negative breast cancer who underwent surgery between 1993 and 2008 at Asan Medical Center. Patients were divided into two cohorts based on adjuvant doxifluridine (Didox; Shin Poong Pharm. Co., Ltd.) administration, and the disease-free survival (DFS) and cancer-specific survival (CSS) was assessed for each cohort. Results: Both cohorts had similar ages and tumor sizes. The DFS and CSS did not significantly differ between the groups (p=0.399 and p=0.126, respectively). When the cohorts were assessed according to human epidermal growth factor receptor 2 (HER2) status, doxifluridine significantly improved DFS among patients with T1aN0 and HER2-positive breast cancer (p=0.037). Conclusion: Doxifluridine did not yield a significant reduction in DFS events in hormone receptor-negative early breast cancer. However, a clear benefit was observed in hormone receptor-negative, HER2-positive T1aN0 breast cancer patients.
참고문헌 (20)
- Gamucci T, "Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis", J Cancer Res Clin Oncol, 139, pp.853~860 (2013)
- Vacek PM, "Increased mammography use and its impact on earlier breast cancer detection in Vermont, 1975-1999", Cancer, 94, pp.2160~2168 (2002)
- Luke C, "Female breast cancers are getting smaller, but socio-demographic differences remain", Aust N Z J Public Health, 28, pp.312~316 (2004)
- Benson JR, "Early breast cancer", Lancet, 373, pp.1463~1479 (2009)
- Hanrahan EO, "Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma", J Clin Oncol, 25, pp.4952~4960 (2007)
- Park Y, "Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study", Br J Cancer, 101, pp.598~604 (2009)
- Ishitsuka H, "Capecitabine: preclinical pharmacology studies", Invest New Drugs, 18, pp.343~354 (2000)
- Tominaga T, "The effect of adjuvant 5’-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial", Int J Oncol, 20, pp.517~525 (2002)
- Ohta Y, "Comparative studies on the immunosuppressive effect among 5’-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil", Gan, 71, pp.190~196 (1980)
- Watanabe T, "Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for breast cancer 01 trial", J Clin Oncol, 27, pp.1368~1374 (2009)
- Albert JM, "Estrogen", progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer, 2010, pp.77, 1296~1302
- Toi M, "Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy", Int J Oncol, 31, pp.899~906 (2007)
- Hortobagyi GN, "A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer", Cancer, 116, pp.2301~2306 (2010)
- Saek T, "A phase II study of S-1 in patients with metastatic breast cancer: a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group", Breast Cancer, 11, pp.194~202 (2004)
- Banerjee S, "Management of small HER2-positive breast cancers", Lancet Oncol, 11, pp.1193~1199 (2010)
- Gonzalez-Angulo AM, "High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller", J Clin Oncol, 27, pp.5700~5706 (2009)
- Curigliano G, "Clinical relevance of HER2 overexpression", amplification in patients with small tumor size and node-negative breast cancer, 2009, pp.27, 5693~5699
- Muss HB, "Adjuvant chemotherapy in older women with early-stage breast cancer", N Engl J Med, 360, pp.2055~2065 (2009)
- "SABCS: CREATE-X: capecitabine is efficacious against residual HER2-negative breast cancer" (2015)[URL]
- McArthur HL, "Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer", Cancer, 117, pp.5461~5468 (2011)